Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow

Rhea-AI Summary

Profound Medical Corp. will announce its Q4 and full year 2023 financial results on March 7, 2024, with a conference call to discuss business developments. The Company develops incision-free therapies for tissue ablation.

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024.

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Fourth Quarter and Full Year 2023 Results Conference Call Details:
Date:	Thursday, March 7, 2024
Time:	4:30 p.m. ET
Live Call Registration:	https://register.vevent.com/register/BI751e786f640f42da89d816e980b66dd6

The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO^® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO^® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO^® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve^® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve^® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

FAQ

When will Profound Medical Corp. announce its Q4 and full year 2023 financial results?

Profound Medical Corp. will announce its Q4 and full year 2023 financial results after market close on Thursday, March 7, 2024.

What does Profound Medical Corp. develop?

Profound Medical Corp. develops customizable, incision-free therapies for the ablation of diseased tissue.

When will the conference call to review the financial results be held?

The conference call to review the financial results will be held at 4:30 p.m. ET on Thursday, March 7, 2024.

Where can the conference call be accessed?

The conference call can be accessed live and archived on the Company's website at www.profoundmedical.com under 'Webcasts' in the Investors section.

What is the ticker symbol for Profound Medical Corp.?

The ticker symbol for Profound Medical Corp. is 'PROF'.